Skip to main content

Catalyst Calendar

Thu, Aug 13, 2026

1 updates

12:05 AM

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

abcellera.com

Tue, Aug 11, 2026

1 updates

4:01 PM

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

abcellera.com

Mon, Aug 10, 2026

1 updates

7:00 AM

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

Trial Results • Phase 2abcellera.com

Fri, Aug 7, 2026

1 updates

4:30 PM

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

Trial Results • Phase 2Top-line results Mon, Aug 10, 2026abcellera.com

Wed, Aug 5, 2026

1 updates

4:05 PM

AbCellera Reports Q2 2026 Business Results

abcellera.com

Wed, Jul 29, 2026

1 updates

7:00 AM

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

abcellera.com

Tue, Jul 7, 2026

1 updates

4:05 PM

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

abcellera.com

Mon, Jul 6, 2026

1 updates

9:00 AM

AbCellera Appoints Dr. Lynn Seely to its Board of Directors

abcellera.com

Wed, Jun 17, 2026

1 updates

7:00 AM

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

abcellera.com

Fri, Jun 5, 2026

1 updates

9:00 AM

AbCellera Appoints Dr. Victor Sandor to its Board of Directors

abcellera.com